Questions 1 – 2: Specify the lymphoma histology (at diagnosis)
Report the lymphoma histology identified at diagnosis. If the recipient has multiple types of lymphoma at diagnosis, seek physician clarification to determine the primary disease at diagnosis.
If the histology at diagnosis is Other B-cell lymphoma or Other T-cell / NK-cell lymphoma, specify the histology.
Transformations
If the recipient had CLL which transformed into DLBCL (Richter’s transformation) or Hodgkin lymphoma (HL), report the DLBCL or HL histology as the histology at diagnosis and the transformation from CLL in Disease Assessment at Transformation. If a transformation from CLL occurred, complete the CLL Pre-Infusion (2013) Form.
If there was a transformation, report the least aggressive lymphoma histology at diagnosis and the most aggressive lymphoma as a transformation below.
Question 3: Assignment of DLBCL (germinal center B-cell type vs. Activated B-cell type) subtype was based on
If the histology at diagnosis is Diffuse, large B-cell lymphoma – Germinal center B-cell subtype or Diffuse, large B-cell lymphoma – Activated B-cell subtype (non-GCB), report the method(s) used to confirm the histology at diagnosis.. If the method of diagnosis is not clear from the available documentation, report Unknown method.
Question 4: Was documentation submitted to the CIBMTR? (e.g., path report from diagnosis)
Indicate whether documents were attached to support the reported histology at diagnosis. Attaching pathology reports at diagnosis in FormsNet3SM may prevent future data queries. For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.
h4Question 5: Were immunohistochemical stains obtained? (at diagnosis, prior to any transformation)
Immunohistochemical staining (IHC) is a process where tissue samples are treated with antibodies and dye. The antibodies bind to specific antigens on the surfaces of the cells, allowing for the identification of those cell surface markers under microscopy. Testing is often documented in the pathology report from the tissue sample, on which IHC was used.
Indicate if IHC was completed at diagnosis.
Questions 6 – 24: Immunohistochemical stain results
Testing may be performed on multiple sample types at diagnosis. Report testing performed on samples taken from the node / mass, if available. If IHC was not done on the node / mass or the results are not known, report testing performed on the bone marrow instead. If IHC results are unclear as this information may be documented differently across hospitals / laboratories, consult a physician.
For each marker, specify if the results were Positive, Negative, or Unknown based on the IHC results at diagnosis. If the report documents “dim” for a specific marker, report this as Positive.
Report Unknown for markers which were not tested or were tested, but the results are not known.
If Positive is reported for any of the markers listed below, indicate whether the percent of cells positive for this marker (as determined by IHC) is known. If Known, report the percent of cells positive for the specified marker.
- BCL-2
- BCL-6
- C-MYC
- Ki-67
If the percentage is documented as a range, report the average. If the percent is documented as less than a specified percent, report the percent specified minus one (e.g., report < 10% as 9%). If the percentage is documented as more than a specified percent, report the percent specified plus one. (e.g., report > 90% as 91%).
Question 25: Were cytogenetics tested (karyotyping or FISH)?
Cytogenetics is the study of chromosomes. This assessment involves testing blood or bone marrow for known chromosomal abnormalities that reflect the recipient’s disease. For more information about cytogenetic testing and terminology, see Appendix C: Cytogenetics.
Indicate whether cytogenetic studies were performed at diagnosis. Do not report any testing performed after treatment was started for the disease histology reported above.
Questions 26 – 27: Were cytogenetics tested via FISH?
Specify if FISH studies were performed at diagnosis and specify if abnormalities were detected.
If FISH studies were not performed at diagnosis, unknown if completed, or if FISH samples were inadequate or the results ‘failed’, report No.
Report chromosomal microarrays / chromosomal genomic arrays as FISH assessments.
See Appendix C: Cytogenetics., for assistance interpreting FISH results.
Questions 28 – 49: Specify FISH abnormalities
For each abnormality specify if it was detected via FISH at diagnosis.
- Report Yes if the abnormality was detected at diagnosis
- Report No if the abnormality was assessed and not detected at diagnosis
- Report Not done if the abnormality was not assessed or could not successfully be performed at diagnosis
If a clonal abnormality is detected, but not listed as an option, select Yes for Other abnormality and specify the abnormality. If multiple other abnormalities were detected, report “see attachment” and attach the final report(s) for any other abnormalities detected.
For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.
Question 50: Was documentation submitted to the CIBMTR? (e.g., FISH report)
Indicate if the FISH report is attached to support the findings reported above.
For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.
Questions 51 – 52: Were cytogenetics tested via karyotyping?
Specify if karyotyping was performed at diagnosis and specify if abnormalities were detected. If karyotyping failed or the sample was inadequate, select Yes and specify the results as No evaluable metaphases.
If karyotyping was not performed at diagnosis or unknown if completed, report No.
See Appendix C: Cytogenetics, for assistance interpreting karyotype results.
Questions 53 – 54: Specify karyotype abnormalities (check all that apply)
Select all abnormalities detected by karyotyping at diagnosis. If a clonal abnormality is detected, but not listed as option, select Other abnormality and specify the abnormality. If multiple other abnormalities were detected, report “see attachment” and attach the final report(s) for any other abnormalities detected.
For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.
Question 55: Was documentation submitted to the CIBMTR? (e.g., karyotyping report)
Indicate if the karyotyping report is attached to support the findings reported above.
For further instructions on how to attach documents in FormsNet3SM, refer to the Training Guide.
Section Updates:
| Question Number | Date of Change | Add/Remove/Modify | Description | Reasoning (If applicable) |
|---|---|---|---|---|
| . | . | . | . | . |
Need more help with this?
Don’t hesitate to contact us here.